Tag:
Synthes
Latest Headlines
Latest Headlines
J&J gains EU nod for $21.3B Synthes deal
It took a year after the initial announcement, but Johnson & Johnson ($JNJ) finally gained European regulatory approval for its $21.3 billion bid to buy Synthes.
Ex-Synthes employee fights back in generic device tussle
Synthes is fighting an ex-employee in court alleging, among other things, illegal use of proprietary information. This week, he's fighting back.
FDA threatens fines, regulatory action over Synthes' GMP problems
Synthes has been producing rods, power tools and screws for orthopedics for years. But now the FDA is putting the screws to Synthes.
FDA warns Synthes facility over complaint handling procedures
Synthes has not had the best couple of weeks. The company, which is facing legal action from families whose loved ones died after receiving a bone cement, is facing other problems--this time from the FDA over problems at its West Chester, PA, facility. That facility makes Click'X 3-D polyaxial heads, Click'X 3-D pedicle screws and N-Hance rods.
Families sue Synthes, former execs over deaths in bone cement case
The effects of the illegal clinical study involving a Synthes bone cement product are still being felt. The families of two patients who died after receiving the cement are suing the company and four former executives in the California Superior Court, alleging wrongful death and elder abuse.
Synthes sues Stryker for 'raiding' sales force, misappropriation of secrets
A Synthes ( $SYST ) unit is accusing rival Stryker ( $SYK ) of raiding its San Francisco-based sales force and using confidential information from those ex-employees to its advantage. In a complaint
Final Synthes exec sentenced in Norian case
A fourth Synthes official has been sentenced to 8 months in prison and ordered to pay $100,000 for a misdemeanor count of shipping adulterated and misbranded medical devices. Richard Bohner's
UPDATED: Ex-Synthes exec sentenced to 9 months in prison
Former Synthes North America President Michael Huggins will serve 9 months in prison for his role in a clinical trial to test bone cement that resulted in the deaths of three people, the AP reported...
Synthes vet tapped as next Nobel Biocare chair
Michel Orsinger, president and CEO of Synthes, is slated to become the next chairman of the board of Nobel Biocare after current Chairman Heino von Prondzynski announced his intention to resign.
Four execs face prison for off-label scheme
Off-label use of a bone cement could send four Synthes executives to prison. After pleading guilty to a misdemeanor, the four men now await sentencing in Pennsylvania, and could become the first
